ProQR Announces Second Quarter 2022 Operating and Financial Results

ProQR Announces Second Quarter 2022 Operating and Financial ResultsProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022Company plans to discuss findings from sepofarsen Illuminate trial...

Related Keywords

United States ,Netherlands ,Sarah Kiely ,Smital Shah ,John Maraganore ,Gerard Platenburg ,Exchange Commission ,Alnylam Pharmaceuticals ,Corporate Development ,European Union ,Nasdaq ,Program Updates ,Second Quarter ,Peptide Therapeutics ,Annual General Meeting ,Chief Corporate Development Officer ,General Counsel ,Chief Scientific Officer ,Chief Business ,Financial Officer ,Chief Financial ,Leber Congenital Amaurosis ,Minimum Bid Price Requirement ,